The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 51-57

  Nordøy, Ingvild ^a   Müller, Fredrik ^a,c   Nordal, Knut P ^b   Rollag, Halvor ^c   Lien, Egil ^d   Aukrust, Pål ^a   Frøland, Stig S ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Section of Nephrology   (Norway)

^c Department of Microbiology ^*  (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DOWN REGULATION; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INTERLEUKIN-10; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0007395546     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315184     Document Type: Article

References (42)

1. 1. Ho M. Cytomegalovirus. Biology and infection. 2nd ed. New York: Plenum Publishing, 1991.
2. 2. Sia IG, Paya CV. Infectious complications following renal transplantation. Surg Clin North Am 1998;78:95-112.
3. 3. De Otero J, Gavaldà J, Murio E, et al. Cytomegalovirus disease is a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998;26:865-70.
4. 4. Michelson S. Mechanisms of immunosuppression by human cytomegalovirus. In: Sholtz M, Rabenau HF, Doerr HW, Cinatl J Jr., eds. CMV related immunopathology. Monographs in Virology vol. 21. Basel: Karger, 1998: 12-28.
5. 5. Miller DM, Sedmak DD. Cytomegalovirus persistence: escape from cell-mediated immunosurveillance. In: Sholtz M, Rabenau HF, Doerr HW, Cinatl J Jr., eds. CMV related immunopathology. Monographs in Virology vol. 21. Basel: Karger, 1998:1-11.
6. 6. van der Berg AP, van Son WJ, Janssen RAJ, et al. The recovery of cytomegalovirus infection is associated with activation of peripheral blood lymphocytes. J Infect Dis 1992;166:1228-35.
7. + T cells. Clin Exp Immunol 1994;95:465-71.
8. + T lymphocytes and cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995;120:283-90.
9. + T cell subset in kidney transplant recipients. Transplantation 1998;65:279-82.
10. 10. Carney WP, Hirsch MS. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis 1981;144:47-54.
11. 11. Timón M, Arnaiz-Villena A, Ruiz-Contreras J, Ramos-Amador JT, Pacheco A, Regueiro JR. Selective impairment of T lymphocyte activation through the T cell receptor/CD3 complex after cytomegalovirus infection. Clin Exp Immunol 1993;94:38-42.
12. 12. Nokta MA, Hassan MI, Loesch K, Pollard RB. Human cytomegalovirus-induced immunosuppression - relationship to tumor necrosis factor-dependent release of arachidonic acid and prostaglandin E(2) in human monocytes. J Clin Invest 1996;97:2635-41.
13. 13. Tilg H, Vogel W, Aulitzky WE, et al. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation 1990;49:1074-80.
14. 14. Humbert M, Devergne O, Cerrina J, et al. Activation of macrophages and cytotoxic cells during cytomegalovirus pneumonia complicating lung transplantation. Am Rev Respir Dis 1992;145:1178-84.
15. 15. Fietze E, Prösen S, Reinke P, et al. Cytomegalovirus infection in transplant recipients. Transplantation 1994;58:675-80.
16. 16. Schwaighoffer H, Oberhuber G, Hebart H, et al. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation. Transplantation 1997;63:52-6.
17. 17. Sparrelid E, Emanuel D, Fehniger T, Andersson U, Andersson J. Interstitial pneumonitis in bone marrow transplant recipients is associated with local production of TH2-type cytokines and lack of T cell-mediated cytotoxicity. Transplantation 1997;63:1782-9.
18. 18. Koskinen PK. The association of the induction of vascular cell adhesion molecule-1 with cytomegalovirus antigenemia in human heart allografts. Transplantation 1993;56:1103-8.
19. 19. Lautenschlager I, Hockerstedt K, Taskinen E, von Willebrand E. Expression of adhesion molecules and their ligands in liver allografts during cytomegalovirus (CMV) infection and acute rejection. Transpl Int 1996; 9(suppl 1):S213-5.
20. 20. Dinarello CA. Role of pro-and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 1997;11:91-103.
21. 21. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994;56:1-26.
22. 22. de Waal Malefyt R, Abrams J, Bennet B, Figdor CG, de Vries JE. Interleukin 10 (11-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174: 1209-20.
23. 23. Kurtzhals JA. Low plasma concentrations of interleukin-10 in severe malaria anaemia compared with cerebral and uncomplicated malaria infection. Lancet 1998;351:1768-72.
24. 24. Stylianou E, Aukrust P, Kvale D, Müller F, Frøland SS. Interleukin (IL)-10 in HIV infection: increasing serum IL-10 levels with disease progression - downregulatory effect of potent antiretroviral therapy. Clin Exp Immunol 1999;116:115-20.
25. 25. Nordøy I, Müller F. Nordal KP, et al. Immunologic parameters as predictive factors of cytomegalovirus infection in renal allograft recipients. J Infect Dis 1999;180:195-8.
26. 26. Grossi P, Minoli L, Percivalle E, Irish W, Vigano, Gerna G. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995;59:847-51.
27. 27. Hestdal K, Aukrust P, Müller F, et al. Dysregulation of membrane-bound tumor necrosis factor α and tumor necrosis factor receptors on mononuclear cells in human immunodeficiency virus type 1: low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load. Blood 1997;90:2670-9.
28. 28. Eggesbø JB, Hjermann I, Lund PK, Joø GB, Øvstebø R, Kierulf P. LPS induced release of IL-1β, IL-6, TNF-α and sCD14 in whole blood and PBMC from persons with high and low HDL-lipoprotein. Cytokine 1994;6:521-9.
29. 29. Rollag H, Sagedal S, Holter E, Degree M, Ariansen S, Nordal KP. Cytomegalovirus infection in kidney transplant recipients by a quantitative RNA-DNA hybrid capture assay for cytomegalovirus DNA in leukocytes. Eur J Microbiol Infect Dis 1998;17:124-7.
30. 30. Lien E, Aukrust P, Sundan A, Müller F, Frøland SS, Espevik T. Elevated levels of serum soluble CD14 in HIV-1 infection: correlation to disease progression and clinical events. Blood 1998;92:2084-92.
31. 31. Asanuma H, Numazaki K. Nagata N, Chiba S. Cytokine response and polymerase chain reaction study of peripheral blood mononuclear cells in infants with human cytomegalovirus infection. FEMS Immunol Med Microbiol 1995;12:153-8.
32. 32. Humbert M, Roux-Lombard P, Cerrina J, et al. Soluble TNF receptors (TNF-sR55 and TNF-sR75) in lung allograft recipients displaying cytomegalovirus pneumonitis. Am J Crit Care Med 1994;149:1681-5.
33. 33. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
34. 34. Stein J, Volk HD, Liebenthal C, Kruger DH, Prösch S. Tumor necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promotor in immature monocytic cells. J Gen Virol 1993;74:2333-8.
35. 35. Haagmans BL, Stals FS, van der Maide PH, Bruggeman CA, Horzinek MC, Schijns VE. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus. J Virol 1994;68:2297-304.
36. 36. Ruzek MC, Pearce BD, Miller AH, Biron CA. Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection. J Immunol 1999;162:3527-33.
37. 37. Oswald IP, Wynn TA, Sher A, James SL. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor α required as a costimulatory factor for interferon γ-induced activation. Proc Natl Acad Sci USA 1992;89:8676-80.
38. 38. Macatonia SE, Doherty TM, Knight SC, O'Garra A. Differential effect of IL-10 in dendritic cell-induced T-cell proliferation and IFNγ production. J Immunol 1993;150:3755-65.
39. 39. Perrin G, Johnson HM, Subramaniam PS. Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of cell cycle. Blood 1999;93:208-16.
40. 40. Taylor-Wiedeman J, Sissons JGP, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in healthy individuals. J Gen Virol 1991;72:2059-64.
41. 41. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promote their maturation to macrophages. Eur J Immunol 1998;28:359-69.
42. 42. Weissman D, Poli G, Fauci AS. Interleukin-10 blocks HIV replication in macrophages by inhibiting the autocrine loop of TNFα and IL-6 induction of virus. AIDS Res Hum Retroviruses 1994;10:1199-206.